Zacks: Analysts Anticipate LHC Group, Inc. (LHCG) Will Post Quarterly Sales of $521.88 Million

Wall Street analysts expect LHC Group, Inc. (NASDAQ:LHCG) to announce $521.88 million in sales for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for LHC Group’s earnings, with the highest sales estimate coming in at $528.60 million and the lowest estimate coming in at $511.07 million. LHC Group posted sales of $502.02 million during the same quarter last year, which suggests a positive year-over-year growth rate of 4%. The business is expected to issue its next earnings results on Wednesday, August 7th.

On average, analysts expect that LHC Group will report full year sales of $2.11 billion for the current year, with estimates ranging from $2.10 billion to $2.12 billion. For the next fiscal year, analysts anticipate that the firm will report sales of $2.23 billion, with estimates ranging from $2.20 billion to $2.27 billion. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover LHC Group.

LHC Group (NASDAQ:LHCG) last released its quarterly earnings results on Wednesday, May 8th. The health services provider reported $0.98 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.90 by $0.08. LHC Group had a net margin of 3.83% and a return on equity of 8.43%. The firm had revenue of $502.59 million during the quarter, compared to analyst estimates of $511.16 million.



Several equities research analysts have recently commented on the stock. BidaskClub raised shares of LHC Group from a “buy” rating to a “strong-buy” rating in a research report on Friday, May 17th. Zacks Investment Research raised shares of LHC Group from a “sell” rating to a “hold” rating in a research report on Saturday, May 11th. Jefferies Financial Group upped their price target on shares of LHC Group from $125.00 to $130.00 and gave the company a “buy” rating in a research report on Thursday, May 9th. Barclays reissued a “hold” rating on shares of LHC Group in a report on Sunday, May 12th. Finally, UBS Group set a $133.00 target price on shares of LHC Group and gave the stock a “buy” rating in a report on Friday, May 10th. Four equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $118.50.

In related news, Director Ronald T. Nixon sold 12,000 shares of the stock in a transaction that occurred on Wednesday, May 22nd. The shares were sold at an average price of $117.20, for a total value of $1,406,400.00. Following the completion of the sale, the director now directly owns 29,100 shares of the company’s stock, valued at approximately $3,410,520. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Keith G. Myers sold 75,000 shares of the stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $108.53, for a total transaction of $8,139,750.00. The disclosure for this sale can be found here. Insiders sold a total of 130,324 shares of company stock valued at $14,222,700 over the last three months. 5.20% of the stock is currently owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in the stock. Citigroup Inc. boosted its stake in LHC Group by 265.2% in the 4th quarter. Citigroup Inc. now owns 4,386 shares of the health services provider’s stock worth $412,000 after purchasing an additional 3,185 shares during the period. Everence Capital Management Inc. boosted its stake in LHC Group by 43.6% in the 1st quarter. Everence Capital Management Inc. now owns 4,050 shares of the health services provider’s stock worth $449,000 after purchasing an additional 1,230 shares during the period. Eqis Capital Management Inc. boosted its stake in LHC Group by 6.2% in the 4th quarter. Eqis Capital Management Inc. now owns 4,837 shares of the health services provider’s stock worth $454,000 after purchasing an additional 281 shares during the period. Campbell Newman Asset Management Inc. boosted its stake in LHC Group by 2.4% in the 1st quarter. Campbell Newman Asset Management Inc. now owns 6,350 shares of the health services provider’s stock worth $704,000 after purchasing an additional 151 shares during the period. Finally, Financial Gravity Companies Inc. bought a new position in LHC Group in the 4th quarter worth approximately $49,000. 93.88% of the stock is owned by institutional investors.

NASDAQ LHCG opened at $114.49 on Monday. LHC Group has a 52 week low of $74.00 and a 52 week high of $122.20. The stock has a market cap of $3.61 billion, a PE ratio of 32.25, a price-to-earnings-growth ratio of 2.02 and a beta of 0.87. The company has a quick ratio of 1.57, a current ratio of 1.57 and a debt-to-equity ratio of 0.21.

LHC Group Company Profile

LHC Group, Inc provides post-acute health care services to patients through its home nursing agencies, hospices and long-term acute care hospitals. The company operates through the following business segments: Home Health Services, Hospice Services, Home & Community-Based Services, Facility-Based Services and Healthcare Innovations.

Recommended Story: What does a market perform rating mean?

Get a free copy of the Zacks research report on LHC Group (LHCG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for LHC Group (NASDAQ:LHCG)

Receive News & Ratings for LHC Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LHC Group and related companies with MarketBeat.com's FREE daily email newsletter.